Randa Mohamed MA Farag
This study was performed to quantify the expression of Golgi protein-73 (GP73) in healthy controls and in patients with disease, and to judge the correlations between GP73 and other serum markers in numerous liver diseases. Study the sensitivity and specificity of Golgi Glypican-73 (GP37) as new biomarker useful in early prediction for malignant hepatoma in hepatitis viruses (HBV, HCV) and in chronic liver Cirrhosis; Also in chronic liver diseases. Serum GP73 was measured in 478 healthy controls and 296 patients with differing types of disease. Quantitative hepatitis B virus (HBV) DNA made up our minds in two chronic hepatitis B (CHB) groups. Other serum liver fibrosis markers were measured within the liver fibrosis group and ?-fetoprotein (AFP) was measured in hepatoma (HCC) group. The correlations between GP73 and these markers were evaluated. The GP73 value in hepatitis B- e-antigen (HBeAg)-positive CHB group, HBeAg-negative CHB group, liver fibrosis group and HCC group was significantly higher (p<0.001) than that in healthy controls. GP73 showed significant correlation with other markers within the liver fibrosis group and with AFP within the HCC group. Compared with healthy controls, GP73 in patients with disease was significantly increased. With the progression of disease, GP73 showed a significantly increasing trend. These results suggest that GP73 may be used as a serum marker for the diagnosis of liver diseases and for monitoring disease progression
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 